Mary Ellen Moynahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2474641/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brca1 Controls Homology-Directed DNA Repair. Molecular Cell, 1999, 4, 511-518.	9.7	1,135
2	BRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks. Molecular Cell, 2001, 7, 263-272.	9.7	897
3	Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Reviews Molecular Cell Biology, 2010, 11, 196-207.	37.0	779
4	Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer. Clinical Cancer Research, 2013, 19, 5505-5512.	7.0	592
5	Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification. Journal of Clinical Oncology, 2001, 19, 2587-2595.	1.6	531
6	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.	7.0	338
7	Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 2011, 3, 75ra25.	12.4	242
8	Double-strand breaks and tumorigenesis. Trends in Cell Biology, 2001, 11, S52-S59.	7.9	180
9	Involvement of Mammalian Mus81 in Genome Integrity and Tumor Suppression. Science, 2004, 304, 1822-1826.	12.6	178
10	Double-strand breaks and tumorigenesis. Trends in Cell Biology, 2001, 11, S52-S59.	7.9	135
11	ATP Hydrolysis by Mammalian RAD51 Has a Key Role during Homology-directed DNA Repair. Journal of Biological Chemistry, 2002, 277, 20185-20194.	3.4	124
12	Eme1 is involved in DNA damage processing and maintenance of genomic stability in mammalian cells. EMBO Journal, 2003, 22, 6137-6147.	7.8	118
13	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2â^' advanced breast cancer: results from BOLERO-2. British Journal of Cancer, 2017, 116, 726-730.	6.4	112
14	The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene, 2002, 21, 8994-9007.	5.9	109
15	BARD1 Participates with BRCA1 in Homology-Directed Repair of Chromosome Breaks. Molecular and Cellular Biology, 2003, 23, 7926-7936.	2.3	108
16	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	1.6	101
17	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
18	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 2018, 36, 981-990.	1.6	95

#	Article	IF	CITATIONS
19	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 154-160.	2.4	91
20	Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5564-5569.	7.1	90
21	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. PLoS ONE, 2012, 7, e51563.	2.5	78
22	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2015, 33, 442-447.	1.6	75
23	Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. Nature Structural and Molecular Biology, 2011, 18, 500-503.	8.2	71
24	When Genome Maintenance Goes Badly Awry. Molecular Cell, 2016, 62, 777-787.	9.7	64
25	BRCA Gene Structure and Function in Tumor Suppression. Cancer Journal (Sudbury, Mass), 2010, 16, 39-47.	2.0	59
26	The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/ <i>neu</i> Overexpressed/Amplified Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1216-1222.	1.6	56
27	PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Research and Treatment, 2011, 129, 635-643.	2.5	49
28	ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7665-7670.	7.1	48
29	Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nature Communications, 2016, 7, 13241.	12.8	36
30	PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS ONE, 2016, 11, e0159341.	2.5	35
31	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	7.0	28
32	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer, 2013, 13, 239-246.e1.	2.4	27
33	Loss of 53BP1 Is a Gain for BRCA1 Mutant Cells. Cancer Cell, 2010, 17, 423-425.	16.8	22
34	A model for testing recombinogenic sequences in the mouse germline. Human Molecular Genetics, 1996, 5, 875-886.	2.9	17
35	Binding, internalization, and degradation of [125I]insulin by cultured bovine aortic endothelial cells: Effects of serotonin. In Vitro, 1983, 19, 833-840.	1.2	13
36	Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. Clinical Breast Cancer, 2008, 8, 418-424.	2.4	12

1

#	Article	IF	CITATIONS
37	BRCA2: safeguarding the genome through homologous recombination. Topics in Current Genetics, 2007, , 363-380.	0.7	3

BRCA2: safeguarding the genome through homologous recombination. , 2007, , 363-380.